. OVERVIEW Background Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment...
Q2 FY2026 — expected 2026-07-22
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001600620-26-000017 | EDGAR | 37K words |
| 2025-02-27 | 2024-12-31 | 0001600620-25-000011 | EDGAR | — |
| 2024-02-15 | 2023-12-31 | 0001600620-24-000012 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0001628280-23-005341 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001628280-22-004082 | EDGAR | — |
| 2021-02-24 | 2020-12-31 | 0001628280-21-003060 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001600620-25-000106 | EDGAR | 12K words |
| 2025-07-31 | 2025-06-30 | 0001600620-25-000092 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001600620-25-000049 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001600620-24-000108 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0001600620-24-000091 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0001600620-24-000051 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001600620-23-000044 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001600620-23-000029 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001600620-23-000012 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001628280-22-027931 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001628280-22-020820 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001628280-22-013439 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-03 | 0001600620-26-000035 | EDGAR | 71K words |
| 2026-03-23 | 0001600620-26-000026 | EDGAR | — |
| 2026-02-26 | 0001600620-26-000015 | EDGAR | — |
| 2025-11-04 | 0001600620-25-000108 | EDGAR | — |
| 2025-07-31 | 0001600620-25-000090 | EDGAR | — |
| 2025-06-30 | 0001600620-25-000083 | EDGAR | — |
| 2025-05-15 | 0001600620-25-000057 | EDGAR | — |
| 2025-05-12 | 0001600620-25-000047 | EDGAR | — |
| 2025-02-27 | 0001600620-25-000009 | EDGAR | — |
| 2024-11-07 | 0001600620-24-000106 | EDGAR | — |
284 total filings indexed. 256 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001600620 |
| Ticker | AUPH |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Website | https://www.auriniapharma.com |
| Listed | 2009-10-21 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report